MRNA 39.39 (-0.43%)
US60770K1079BiotechnologyBiotechnology

Moderna (MRNA) Stock Highlights

39.39 | -0.43%
2024-12-21 00:38:05
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firms mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Statistics

Range Today
39.12 40.83
Volume Today 35.02M
Range 1 Year
35.8 170.47
Volume 1 Year 1.26B
Range 3 Year
35.8 321.3
Volume 3 Year 3.85B
Range 10 Year
11.54 497.49
Volume 10 Year 12.2B

Highlights

Market Capitalization 18.02B (large)
Floating Shares 347.65M
Current Price 39.39
Price To Earnings -8.68
Price To Revenue 2.71
Price To Book 1.51
Earnings Per Share -5.81
Payout Ratio 0%

Performance

Latest -0.43%
1 Month +5.63%
3 Months -41.73%
6 Months -70.28%
1 Year -55.71%
3 Years -87.74%
5 Years +103.04%
10 Years +79.05%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.